The Condition That Affects 1 in 8 Women Just Got a New Name. Here’s Why It Matters in Menopause.

A recent landmark announcement changed the name of one of the most common and most misunderstood hormonal conditions in women’s health. Polycystic Ovary Syndrome, long known as PCOS, has been renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS, through a landmark global consensus process.

The change, published in The Lancet and backed by more than 50 patient and professional organizations worldwide, reflects something researchers and advocates have known for years: this condition was never really about cysts. It’s a complex, long-term hormonal disorder with far-reaching effects on metabolism, mental health, skin, weight, and the reproductive system. And for millions of women entering perimenopause and menopause, it’s a story that deserves far more attention.

Why the name change matters so much

For decades, the word “polycystic” sent doctors, patients, and researchers looking in one direction: the ovaries. But as Professor Helena Teede, the endocrinologist who led the global name change process, put it: “There is actually no increase in abnormal cysts on the ovary.”

The old name contributed to missed diagnoses, limited awareness, and inadequate care for a condition far more complex than its label suggested. The new name, PMOS, leads with what the condition truly is: a polyendocrine condition, meaning multiple hormones are involved, and a metabolic disorder. That single shift in framing demands that the condition finally be taken as seriously as it deserves.

PMOS and menopause: the connection most women never hear about

If you have PMOS, your hormonal story doesn’t wrap up neatly when your periods become irregular. It gets more complicated. Here’s what the research tells us.

The transition may happen later, but it can be harder to spot.

Emerging research suggests women with PMOS may enter the later stages of the menopause transition somewhat later than women without the condition, possibly reflecting prolonged ovarian function and a larger follicle pool. However, the evidence is still evolving, and not all studies have found a clear difference in age at menopause.

That possibility can sound like good news, and in some ways it may be. But it also highlights a practical challenge: perimenopause, which is already easy to miss, can be especially difficult to identify for women who have spent years navigating irregular cycles. When your period has always been unpredictable, how do you know when perimenopause begins? Many women with PMOS may attribute new symptoms to their existing condition, rather than recognizing that the menopause transition may also be underway.

Metabolic health deserves extra attention in midlife.

PMOS is already associated with insulin resistance, higher risk of type 2 diabetes, and increased cardiovascular risk factors. Menopause is also a time when cardiometabolic health becomes more important, and more at risk, particularly as estrogen declines and body fat distribution often shifts toward the abdomen.

Researchers are still working to untangle exactly how PMOS and the menopause transition interact. But the overlap matters. For women with PMOS, midlife is an especially important time to stay proactive about metabolic monitoring, preventive care, and lifestyle support.

Androgen levels shift in complex ways.

PMOS is associated with higher androgen levels, and research suggests that this pattern can persist into peri- and postmenopause. That may help explain why symptoms such as unwanted facial hair or scalp hair thinning can remain relevant in midlife.

Researchers are still working to understand how PMOS may shape the broader menopause experience, including symptom patterns beyond the menstrual cycle. What is clear is that menopause does not erase the underlying hormonal complexity of PMOS.

Mental health deserves its own conversation.

PMOS carries a significantly elevated risk of anxiety and depression, and perimenopause is also a time of increased vulnerability to mood symptoms. For women navigating both, mental health deserves to be part of the conversation, not an afterthought.

The emotional weight can be substantial, and the risk of it being dismissed or attributed to “just hormones” is real. Naming both conditions accurately is one step toward getting appropriate, holistic support.

What to do with this information

If you have PMOS, or have ever been told you had PCOS, the most important thing you can take from this news is this: your condition is real, it is complex, and it does not stop mattering at menopause. It may shape your perimenopause experience, your metabolic health, and your emotional wellbeing in ways that are increasingly being studied, but still too rarely communicated.

Talk to your provider using the new name. Ask specifically how PMOS might be influencing your perimenopause or menopause experience. Bring up metabolic monitoring, mental health support, and any menopause-related changes affecting your quality of life as part of the same conversation. You are allowed to expect care that sees the whole picture.

And know that after 14 years of global collaboration, 22,000 survey responses, and the work of advocates, researchers, and women with lived experience around the world, the conversation is finally catching up to what your body has been telling you all along.

Sources

• Teede et al., “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome,” The Lancet (May 12, 2026)
• Endocrine Society press release: “Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care…” (May 12, 2026)
• Lavi et al., “Women with PCOS have a later menopausal transition and a lower prevalence of menopausal symptoms at age 46,” Acta Obstetricia et Gynecologica Scandinavica (2026)
• Millán-de-Meer et al., “PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis,” Human Reproduction Update (2023)
• 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS, Monash University resource page